サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534008

急性呼吸困難症候群治療の世界市場

Acute Respiratory Distress Syndrome Treatment

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
急性呼吸困難症候群治療の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

急性呼吸困難症候群治療の世界市場は2030年までに43億米ドルに達する見込み

2023年に31億米ドルと推定される急性呼吸困難症候群治療の世界市場は、分析期間2023-2030年にCAGR 4.9%で成長し、2030年には43億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口投与は、CAGR 4.8%を記録し、分析期間終了時には21億米ドルに達すると予測されます。注射投与セグメントの成長率は、分析期間中CAGR 6.0％と推定されます。

米国市場は8億3,400万米ドルと推定、中国はCAGR 8.0％で成長予測

米国の急性呼吸困難症候群治療市場は、2023年に8億3,400万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億8,000万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と5.0%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の急性呼吸困難症候群治療市場- 主要動向と促進要因まとめ

急性呼吸窮迫症候群（ARDS）は、肺の広範囲に及ぶ炎症の急速な発症を特徴とする、生命を脅かす重篤な疾患です。ARDSは、肺炎、敗血症、外傷、有害物質の吸入など、さまざまな基礎疾患から生じる可能性があります。ARDSの治療は主に、肺機能の維持と根本的な原因への対処に重点を置く。十分な酸素化を確保するために機械的換気が必要となることが多く、さらなる肺損傷を最小限に抑えるために低タイド量換気などの戦略が採用されます。患者をうつぶせに寝かせる腹臥位も、血流を再分配し肺の圧迫を減らすことで酸素化を改善することができます。体外膜酸素療法（ECMO）のような補助療法は、従来の機械的換気では不十分な重症例に使用されます。

機械的補助に加えて、薬理学的介入がARDS管理において重要な役割を果たします。副腎皮質ステロイドは炎症を抑え、転帰を改善するために一般的に投与されます。換気を促進し酸素化を改善するために、神経筋遮断薬などの他の薬剤が使用されることもあります。輸液管理は非常に重要であり、輸液過多と肺水腫の悪化を防ぐために保存的アプローチがしばしば採用されます。新たな治療法や現在進行中の調査では、損傷した肺組織の修復と再生を目的とした幹細胞治療や、抗炎症作用を有するスタチンの使用などの治療法の可能性が模索されています。ARDS治療は複雑であるため、患者の転帰を最適化するために、肺専門医、重症治療専門医、呼吸療法士が協力する集学的アプローチが必要です。

ARDS治療市場の成長は、いくつかの要因によってもたらされます。医療技術の進歩により診断能力が大幅に向上し、ARDS管理に不可欠な早期発見と介入が可能になった。重症感染症や慢性疾患など、ARDSを引き起こす可能性のある疾患の有病率が上昇しているため、効果的な治療オプションに対する需要が高まっています。さらに、COVID-19の大流行は、高度な呼吸器サポートの重要な必要性を浮き彫りにし、ARDS治療に対する技術革新と投資の加速につながっています。また、治療法を個々の患者のプロファイルに合わせて調整し、有効性と転帰を改善する個別化医療も重視されるようになっています。クリティカルケア医療の研究開発に対する政府および民間セクターの資金援助が市場をさらに後押しし、ARDSに対する新たな治療オプションの開発が促進されています。

調査対象企業の例（注目の全86社）

  • Advocate Health Care, Inc.
  • Aqualung Therapeutics
  • Athersys, Inc.
  • BioAegis（R）Therapeutics Inc.
  • Dragerwerk AG & Co. KGaA
  • Eurosets S.R.L.
  • Fisher & Paykel Healthcare Corporation Ltd.
  • Gen1E Lifesciences
  • Getinge AB（Getinge Group）
  • HEALIOS K.K.
  • Medtronic UK
  • North Memorial Health
  • Roche Diagnostics International AG
  • Savara, Inc.
  • Veru, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP27137

Global Acute Respiratory Distress Syndrome Treatment Market to Reach US$4.3 Billion by 2030

The global market for Acute Respiratory Distress Syndrome Treatment estimated at US$3.1 Billion in the year 2023, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Injection Administration segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$834.0 Million While China is Forecast to Grow at 8.0% CAGR

The Acute Respiratory Distress Syndrome Treatment market in the U.S. is estimated at US$834.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$880.0 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Acute Respiratory Distress Syndrome Treatment Market - Key Trends and Drivers Summarized

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition characterized by rapid onset of widespread inflammation in the lungs. ARDS can result from various underlying conditions such as pneumonia, sepsis, trauma, or inhalation of harmful substances. The treatment of ARDS primarily focuses on supporting lung function and addressing the underlying cause. Mechanical ventilation is often necessary to ensure adequate oxygenation, and strategies such as low tidal volume ventilation are employed to minimize further lung injury. Prone positioning, where patients are laid on their stomachs, can also improve oxygenation by redistributing blood flow and reducing lung compression. Adjunctive therapies like extracorporeal membrane oxygenation (ECMO) may be used in severe cases where conventional mechanical ventilation is insufficient.

In addition to mechanical support, pharmacological interventions play a crucial role in ARDS management. Corticosteroids are commonly administered to reduce inflammation and improve outcomes. Other medications, such as neuromuscular blockers, may be used to facilitate ventilation and improve oxygenation. Fluid management is critical, with a conservative approach often adopted to prevent fluid overload and worsening lung edema. Emerging treatments and ongoing research are exploring the potential of therapies such as stem cell treatment, which aims to repair and regenerate damaged lung tissue, and the use of statins, which have anti-inflammatory properties. The complexity of ARDS treatment necessitates a multidisciplinary approach, involving pulmonologists, critical care specialists, and respiratory therapists working together to optimize patient outcomes.

The growth in the ARDS treatment market is driven by several factors. Advances in medical technology have significantly improved diagnostic capabilities, allowing for earlier detection and intervention, which is crucial for ARDS management. The rising prevalence of conditions that can lead to ARDS, such as severe infections and chronic illnesses, is increasing the demand for effective treatment options. Additionally, the COVID-19 pandemic has highlighted the critical need for advanced respiratory support, leading to accelerated innovation and investment in ARDS treatments. There is also a growing emphasis on personalized medicine, where treatments are tailored to individual patient profiles, improving efficacy and outcomes. Government and private sector funding for research and development in critical care medicine further propels the market, fostering the development of new and improved therapeutic options for ARDS.

Select Competitors (Total 86 Featured) -

  • Advocate Health Care, Inc.
  • Aqualung Therapeutics
  • Athersys, Inc.
  • BioAegis(R) Therapeutics Inc.
  • Dragerwerk AG & Co. KGaA
  • Eurosets S.R.L.
  • Fisher & Paykel Healthcare Corporation Ltd.
  • Gen1E Lifesciences
  • Getinge AB (Getinge Group)
  • HEALIOS K.K.
  • Medtronic UK
  • North Memorial Health
  • Roche Diagnostics International AG
  • Savara, Inc.
  • Veru, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Acute Respiratory Distress Syndrome Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of ARDS Due to COVID-19 and Other Respiratory Infections
    • Advances in Critical Care and Respiratory Therapies
    • Increasing Investment in ARDS Research
    • Development of Novel Therapeutics and Interventions
    • Expansion of Clinical Trials for ARDS Treatments
    • Growing Demand for Mechanical Ventilation and ECMO
    • Integration of Personalized Medicine in ARDS Treatment
    • Technological Innovations in Respiratory Support Devices
    • Rising Awareness and Diagnosis Rates
    • Patient Access and Reimbursement Issues
    • Increasing Focus on Early Intervention and Prevention
    • Growth of Telemedicine and Remote Monitoring
    • Expansion of Healthcare Infrastructure and ICU Capacity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Respiratory Distress Syndrome Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injection Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Inhalation Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION